VOL. XCIV, NO. 247
WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES
Stock Profile
Veeva Systems Inc. (VEEV) Moat Analysis
Veeva Systems Inc.
VEEV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Veeva is a life-sciences vertical software and data company. Q2 FY2027 revenue shares were 43.9% Commercial Solutions and 56.1% R&D and Quality Solutions; product-area operating income is not disclosed. The only independently scored mechanism in each area is regulated data-and-workflow switching friction. ISO/GxP controls and suite breadth reinforce migration and revalidation work but are not separate moats; Data Cloud is not independently scored because source exclusivity, comparative coverage and accuracy, retention, and standalone economics are undisclosed. Q2 revenue rose 18% to $927.963m and GAAP operating income was $275.018m. Vault CRM had more than 180 customers live, including five top-20 biopharmas, but the legacy Salesforce-platform migration and Salesforce Life Sciences Cloud remain material risks.
Primary segment
R&D Solutions
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 8 tags
Updated 2026-09-05
Segments
Commercial Solutions
Life sciences commercial operations cloud software and data (CRM, content, omnichannel, reference data, analytics)
Revenue
43.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
R&D Solutions
Life sciences R&D, clinical, regulatory, safety, and quality cloud applications (Vault platform-based suites)
Revenue
56.1%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Commercial Solutions
Life sciences commercial operations cloud software and data (CRM, content, omnichannel, reference data, analytics)
Q2 FY2027 product-area revenue was $407131 thousand / $927,963 thousand total, including subscription and services. Product-area operating income remains undisclosed. Source: https://ir.veeva.com/news/news-details/2026/Veeva-Announces-Fiscal-2027-Second-Quarter-Results/default.aspx Data-source exclusivity and comparative coverage remain unproven.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Vault CRM and adjacent commercial applications consolidate customer data, content, and team workflows in one database, creating migration, integration, retraining, and validation work. More than 150 customers were live and 27 were added in Q1, but the ongoing migration from Salesforce also proves that displacement is possible and adds execution risk.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Successful competitive displacement (especially Salesforce Life Sciences Cloud)
- Customer push for interoperability and easier data portability
- Execution risk migrating legacy CRM customers to Vault CRM
Leading indicators
- Biopharma CRM retention and win/loss in top accounts
- Vault CRM migration progress vs plan
- Net revenue retention / renewal rates in Commercial Solutions
Counterarguments
- CRM functionality can be substituted by horizontal platforms with sufficient life sciences configurations
- Large customers can multi-vendor and negotiate pricing; switching may be episodic but still happens
R&D Solutions
Life sciences R&D, clinical, regulatory, safety, and quality cloud applications (Vault platform-based suites)
Q2 FY2027 product-area revenue was $520832 thousand / $927,963 thousand total, including subscription and services. Product-area operating income remains undisclosed. Source: https://ir.veeva.com/news/news-details/2026/Veeva-Announces-Fiscal-2027-Second-Quarter-Results/default.aspx Suite breadth and compliance controls reinforce the existing workflow mechanism.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Vault can unify important clinical, regulatory, safety, and quality documents and structured data in one validated global system. Replacing it can require data migration, integrations, process redesign, user retraining, and regulatory revalidation. Strength is capped below exceptional because customers remain multi-vendor and can replace modules over time.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Customers adopt best-of-breed point solutions and integrate instead of standardizing on Vault
- Data portability standards and migration tooling reduce lock-in
- Platform disruption (new architectures/AI-native competitors) changes buying criteria
Leading indicators
- Vault product expansion per customer (more applications adopted)
- Renewal and expansion rates in R&D Solutions
- Competitive displacement in major R&D/quality evaluations
Counterarguments
- Many enterprises remain multi-vendor in R&D/quality and can replace modules over time
- Large incumbent vendors can bundle and discount to win suite decisions
Evidence
single Vault database
Veeva describes Vault CRM as unifying commercial teams on a shared database, implying material data/workflow switching friction.
Veeva CRM will be supported until December 31, 2029
Legacy Veeva CRM runs on Salesforce, with support continuing through December 31, 2029. Moving to Vault CRM takes work that may keep customers with Veeva, but also creates execution risk.
27 new Vault CRM customers in the quarter
Current Q1 FY2027 evidence that the Vault CRM migration is adding customers, with management also disclosing more than 150 customers live.
More than 180 customers were live on Vault CRM, including five top-20 biopharmas. Twelve top-20 commitments include future migrations and are not all live deployments.
manage important documents and related data in a single global system
A shared document-and-data system across regulated processes creates migration and workflow redesign costs.
Showing 5 of 6 sources.
Risks & Indicators
Erosion risks
- Successful competitive displacement (especially Salesforce Life Sciences Cloud)
- Customer push for interoperability and easier data portability
- Execution risk migrating legacy CRM customers to Vault CRM
- Customers adopt best-of-breed point solutions and integrate instead of standardizing on Vault
- Data portability standards and migration tooling reduce lock-in
- Platform disruption (new architectures/AI-native competitors) changes buying criteria
Leading indicators
- Biopharma CRM retention and win/loss in top accounts
- Vault CRM migration progress vs plan
- Net revenue retention / renewal rates in Commercial Solutions
- Vault product expansion per customer (more applications adopted)
- Renewal and expansion rates in R&D Solutions
- Competitive displacement in major R&D/quality evaluations
Research VEEV elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.